ArticleTheranostics2020
The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Radionuclide theranostics: advances and clinical applications in lung cancer.Frontiers in oncology · 2026Review
- Review
- The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.Protein & cell · 2025Review
- Targeting of Epithelial Cell Adhesion Molecule-Expressing Malignant Tumors Using an Albumin-Binding Domain-Fused Designed Ankyrin Repeat Protein: Effect of the Molecular Architecture.International journal of molecular sciences · 2025Article
- Antibody-drug conjugates in cancer therapy: applications and future advances.Frontiers in immunology · 2025Review
- Unlocking the potential of bispecific ADCs for targeted cancer therapy.Frontiers of medicine · 2024Review
- Exploring the next generation of antibody-drug conjugates.Nature reviews. Clinical oncology · 2024Review
- Evaluation of Chelator-to-Antibody Ratio on Development ofInternational journal of molecular sciences · 2023Article
- Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment.Molecules (Basel, Switzerland) · 2023Review
- Radionuclide-based theranostics - a promising strategy for lung cancer.European journal of nuclear medicine and molecular imaging · 2023Review
- Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.Molecular pharmaceutics · 2023Article
- A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.Cancer research · 2022Article
- Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies.Current treatment options in oncology · 2022Review
- Exploiting protease activation for therapy.Drug discovery today · 2022Review
- Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed.Biomarker research · 2022Review
- Review
- Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and Therapies.Frontiers in oncology · 2022Review
- Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives.Pharmaceutics · 2021Review
- Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable Antibodies.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probody
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.